Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumonia

Chest

Volumn 132, Issue 3, 2007, Pages 1101-1102

  Potoski, Brian A ^a   Paterson, David L ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

BACTERIAL PNEUMONIA; CROSS INFECTION; HUMAN; METABOLISM; NOTE; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; METHICILLIN RESISTANCE; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 35448970960     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.06-2839     Document Type: Letter

References (7)

1. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-955 (Pubitemid 44583720)
2. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-942 (Pubitemid 39447034)
3. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57(suppl 2):S4-S9
4. Rybak MJ, Capelletty DM, Ruffing MJ, et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for gram-positive infections [abstract A-46]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997; 9
5. Drew RH, Lu I, Joyce M, et al. Lack of relationship between predicted area under the time-concentration curve/minimum inhibitory concentration and outcome in vancomycin-treated patients with Staphylococcus aureus bacteremia [abstract A-1493]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004; 36
6. Ebert S. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus [abstract 439]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington, DC: American Society for Microbiology, 1987; 173
7. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/ static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42(suppl 1):S13-S24 (Pubitemid 41832061)